Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Current Assets (2022 - 2025)

Stoke Therapeutics has reported Current Assets over the past 4 years, most recently at $305.7 million for Q4 2025.

  • Quarterly results put Current Assets at $305.7 million for Q4 2025, up 31.34% from a year ago — trailing twelve months through Dec 2025 was $305.7 million (up 31.34% YoY), and the annual figure for FY2025 was $305.7 million, up 31.34%.
  • Current Assets for Q4 2025 was $305.7 million at Stoke Therapeutics, up from $272.4 million in the prior quarter.
  • Over the last five years, Current Assets for STOK hit a ceiling of $375.7 million in Q1 2025 and a floor of $193.3 million in Q1 2024.
  • Median Current Assets over the past 4 years was $267.3 million (2022), compared with a mean of $266.6 million.
  • Biggest five-year swings in Current Assets: dropped 28.48% in 2024 and later skyrocketed 94.4% in 2025.
  • Stoke Therapeutics' Current Assets stood at $244.1 million in 2022, then decreased by 11.77% to $215.3 million in 2023, then grew by 8.09% to $232.8 million in 2024, then skyrocketed by 31.34% to $305.7 million in 2025.
  • The last three reported values for Current Assets were $305.7 million (Q4 2025), $272.4 million (Q3 2025), and $270.0 million (Q2 2025) per Business Quant data.